# An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

> **NCT00398528** · — · TERMINATED · sponsor: **Neurognostics** · enrollment: 48 (estimated)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer acetate, (Copaxone®)
- **DRUG:** IFN-β-1a, (Avonex®)

## Key facts

- **NCT ID:** NCT00398528
- **Lead sponsor:** Neurognostics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 48 (ESTIMATED)
- **Why stopped:** rate of enrollment
- **Last updated:** 2007-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398528, "An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00398528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*